公开(公告)号：US20240226104A1

公开(公告)日：2024-07-11

申请号：US18556250

申请日：2022-04-20

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Wei Gao ,  Duxin Sun ,  Fei Wen ,  Ruiting Li ,  Hongxiang Hu ,  Luke F. Bugada ,  Yudong Song ,  Mahamadou Djibo

IPC: A61K31/519 ,  A61K9/00 ,  A61K9/51 ,  A61K31/337 ,  A61P35/04

CPC classification number: A61K31/519 ,  A61K9/0019 ,  A61K9/5169 ,  A61K31/337 ,  A61P35/04

Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors, and compositions, nanoformulations and methods for treating diseases or disorders (e.g., breast cancer, pancreatic cancer, lung cancer, and lymphoma) with PBK inhibitors or composition thereof. Disclosed herein is a composition comprising: an effective amount of a PI3K inhibitor or a pharmaceutically acceptable salt thereof; and an albumin nanoparticle.

公开(公告)号：US20230183282A1

公开(公告)日：2023-06-15

申请号：US17995254

申请日：2021-04-01

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Duxin Sun ,  Wei Gao ,  Hongxiang Hu ,  Mohamed Dit Mady Traore ,  Yudong Song ,  Bo Wen ,  Miao He ,  Hebao Yuan ,  Ruiting Li

IPC: C07H7/06 ,  A61P31/12 ,  A61K9/127 ,  A61K9/51

CPC classification number: C07H7/06 ,  A61P31/12 ,  A61K9/127 ,  A61K9/5169

Abstract: The present invention relates to methods, compounds, and compositions for treating viral infections, including COVID-19 viral infections. In certain embodiments, the compositions comprise: i) a remdesivir analog, ii) remdesivir or a remdesivir analog, and a surfactant, a cyclodextrin, or a combination thereof, iii) nanoparticles comprising albumin and remdesivir or remdesivir analog, iv) liposomes comprising lipids and remdesivir or remdesivir analog; and/or v) microparticles comprising PLA and/or PLGA, and remdesivir or remdesivir analog. In certain embodiments, the compositions are aqueous (e.g., for intravenous administration). In other embodiments, the compositions are nebulized or in the form of a dry powder (e.g., for inhalation by an infected subject).